# File Descriptions

`Hie2022_C143_Kd` - Binding energy of unmatured, patient-derived antibody that binds the SARS-CoV-2 Wuhan-Hu-1 Spike but was isolated before extensive in vivo somatic hypermutation. (KD, nM)

`Hie2022_mAb114_Kd` - Binding energy of matured, patient-derived antibody that neutralizes ebolavirus by binding to its glycoprotein. (KD, nM)

`Hie2022_MEDI8852_Kd` - Binding energy of highly matured, broadly neutralizing antibody (bnAb) that binds influenza A hemagglutinin (HA) across variants of both major phylogenetic groups (group 1 and group 2) and that reached phase 2 clinical trials. (KD, nM)

`Hie2022_MEDI8852UCA_Kd` - Binding energy of unmatured, inferred germline sequence of MEDI8852, which only neutralizes viruses with group 1 HAs. (KD, nM)

`Hie2022_REGN10987_Kd` - Binding energy of matured, patient-derived antibody that binds early variants of SARS-CoV-2 Spike. (KD, nM)

`Hie2022_S309_Kd` - Binding energy of matured, patient-derived antibody that cross-neutralizes the sarbecoviruses severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by binding to the spike glycoprotein (Spike). (KD, nM)

`Koenig2017_g6_Kd` - Binding energy of a well optimized, high affinity anti-VEGF antibody G6.31. (KD, nM)

`Rosace2023_Adalimumab_Kd` - Binding energy of clinically approved antibody adalimumab bound to TNF-α, where adalimumab had no self-association or cross-reactivity flags. (KD, nM)

`Rosace2023_CR3022_Kd` - Binding energy of antibody obtained from SARS CoV-1 patient, also capable of neutralizing SARS CoV-2 and some of its variants of concern. (KD, nM)

`Rosace2023_Golimumab_Kd` - Binding energy of clinically approved antibody Golimumab bound to TNF-α, where Golumumab had several self-association and cross-reactivity flags. (KD, nM)

`Shanehsazzadeh2023_trastuzumab_multi_kd` - Binding energy of Trastuzumab multi-step multi-CDR designs bound to HER2. (KD, nM)

`Shanehsazzadeh2023_trastuzumab_zero_kd` - Binding energy of Trastuzumab zero-shot CDR H3 designs bound to HER2. (KD, nM)

`Warszawski2019_d44_Kd` - Binding energy of mutants of the anti-lysozyme antibody D44.1. (KD, nM)

`gsk2023_AM14_exp` - Expression of AM14 engineered antibody (KD, nM)

`gsk2023_D25_exp` - Expression of D25 engineered antibody (KD, nM)

`gsk2023_MOTA_exp` - Expression of MOTA engineered antibody (KD, nM)

`gsk2023_RSB1_exp` - Expression of RSB1 engineered antibody (KD, nM)
